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A B S T R A C T
Scedosporium species are fungal opportunistic pathogens frequently seen in chronic lung diseases such as in cystic
ﬁbrosis (CF). They can cause a wide spectrum of diseases mainly in immunodeﬁcient patients. Invasive, dis-
seminated infections with poor prognosis have been described after lung transplantation. We present a CF-
patient with disseminated Scedosporium apiospermum infection after lung transplantation. The patient had skin,
surgical wound, spinal cord, and brain involvements. She recovered fully after prolonged course of voriconazole
treatment.
1. Introduction
Cystic ﬁbrosis (CF) is an inherited disease due to mutations in the
cystic ﬁbrosis transmembrane conductance regulator (CFTR) gene [1].
Defective CFTR protein causes abnormal ion transport across the apical
surfaces of epithelia in multiple organ systems. One consequence of
abnormal ion transport in the lung is dehydration and thickening of
airway secretions. The disease is characterized by recurrent bacterial
and fungal infections and progressive respiratory failure. Lung trans-
plantation (LT) is a therapeutic option for patients with end-stage lung
disease.
Scedosporium is a saprophytic fungus isolated from soil, polluted
water and plant residues worldwide. The genus Scedosporium consists of
three medically important species: Scedosporium apiospermum
(S.apiospermum), Scedosperium boydii (formerly Pseudoallescheria boydii)
and Scedosporium aurantiacum [2]. Scedosporium spp. is the second most
prevalent opportunistic fungus after Aspergillus spp. found to colonize
chronic lung diseases such as CF [3]. The role and pathogenicity of S.
apiospermum in lung diseases is controversial, but either local or dis-
seminated infections are described in immunodeﬁcient patients [4].
Especially after organ transplant, the colonization may develop into
invasive, disseminated infection with central nervous system (CNS)
involvement leading to dismal outcome [5]. Thus, Scedosporium colo-
nization prior to LT is considered as a contra-indication in some
transplantation centers [3]. Unlike Aspergillus, Scedosporium spp. is in-
herently resistant to many antifungals such as amphotericin B and
echinocandins. Voriconazole used alone or in combination is reported
to be the most active agent against Scedosporium [6]. Also, a reduction
in immunosuppression or surgical drainage should be considered when
suitable.
Here, we present the ﬁrst successfully treated disseminated S.
apiospermum CNS infection after a lung transplantation.
2. Case
An 18-year-old woman with CF was considered as a candidate for
bilateral LT. Her respiratory failure had advanced, so that a supple-
mental oxygen therapy and night-time non-invasive ventilation were
initiated. Bilateral pneumothoraxes with subcutaneous emphysema
were detected on an elective control in March 2015. At that time, her
FEV1 had decreased to 1.35 L (34% of predicted). She was referred to
the respiratory department where her ventilatory failure acutely pro-
gressed. After a short resuscitation she was connected to ventilator and
subsequently to extracorporeal membrane oxygenation (ECMO). She
was listed for a Scandinavian emergency LT. S. apiospermum was de-
tected in fungal culture of the tracheal aspirate with susceptibility
testing showing minimal inhibitory concentrations of: voriconazole
0.125mg/L, itraconazole 6mg/L, posaconazole 6mg/L and amphoter-
icin B 12mg/L. After ﬁve days on ECMO, she underwent a bilateral LT
(deﬁned as day 0). Pseudomonas aeruginosa and S. apiospermum colo-
nizations were detected in the extracted native lungs. The peri-opera-
tive course was complicated by pseudomonas septicemia which was
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treated with intravenous (IV) tazobactam/piperacillin, tobramycin, and
oral ciproﬂoxacin with a good clinical outcome. IV caspofungin was
started postoperatively for antifungal prophylaxis with a single loading
dose of 70mg, followed by 50mg daily for 17 days.
Her baseline immunosuppression regimen consisted of tacrolimus,
mycophenolate mofetil, and prednisolone. Prophylactic valganciclovir,
azithromycin, trimethoprim/sulfamethoxazole and nebulized colistin
and amphotericin B were initiated.
The ﬁrst postoperative bronchoscopy at day 30 postoperatively re-
vealed normal anastomotic healing process and otherwise unremark-
able endobronchial ﬁndings. Bacterial and fungal cultures of bronch-
oalveolar lavage (BAL) were negative. Histological acute minimal
rejection (A1B1) was detected in transbronchial lung biopsy (TBB). The
patient was not treated with additional corticosteroids considering her
good clinical condition and previous infections and colonizations.
At the second control visit 60 days postoperatively, she presented
with upper back pain that radiated to the left leg. Symmetric, painful,
palpable, and slightly pigmented nodules with small ulcerations had
appeared on both legs (Fig. 1). The surgical wound had started to se-
crete. She had no fever. Her C-reactive protein was 31 mg/l, ery-
throcyte sedimentation rate 58 mm/h and leukocyte level 9.8 E9/l.
Systemic fungal infection was suspected, and IV voriconazole was in-
itiated at 300mg twice a day for 24 hours and at 200mg twice a day
thereafter. At that time, her immunosuppression consisted of pre-
dnisolone, tacrolimus and mycophenolate mofetil. The latter was dis-
continued due to suspicion of systemic infection. Control bronchoscopy
with TBB revealed no histological signs of rejection. In the following
days, she developed neurological symptoms: headache, nausea, vertigo
and her right side of the mouth was slightly dropped. Also, her left leg
was numb, and the muscular strength was decreased. Computerized
tomography showed no inﬁltrates in the lung parenchyma but there
were small subcutaneous collections under the sternotomy. Brain
magnetic resonance imaging (MRI) revealed multiple ring-enhancing
lesions with perifocal oedema compatible with abscesses (Fig. 2a and
b). Spine MRI showed oedema and multiple abscesses as well in cervical
and thoracic spinal cord (Fig. 2c). Subsequently, the histopathological
ﬁndings from initial skin nodule revealed septal panniculitis with
fungal culture and nucleic acid test positive for S. apiospermum. S.
apiospermum was also cultured from BAL ﬂuid and the surgical wound
secretion. Multiple blood cultures were taken with no signs of fun-
gemia. We refrained from CNS biopsy due to consisted cultural ﬁndings
matching with radiological appearance.
Neurological symptoms vanished gradually, and the patient was
discharged from the hospital after three weeks of treatment.
Intravenous voriconazole was continued at home for ten months.
Miltefosine was combined to the therapy one month after initiation of
voriconazole but it was discontinued after two days due to nausea,
interactions with tacrolimus and on the other hand good clinical re-
sponse to voriconazole. MRIs and clinical status were controlled every
one to four months. After ten months of intravenous administration
voriconazole was switched to oral tablets with a dose of 300mg twice
daily. Therapeutic serum levels were conﬁrmed by repeated measure-
ments (target therapeutic limits 2–5.5mg/l). At a control visit in June
2018 three years after LT and 35 months of treatment, the voriconazole
treatment was terminated. After the discontinuation of antifungal
treatment, the patient has visited our clinic for two controls with no
signs of fungal re-infection. The last visit was in January 2019, nearly
four years after the LT and eight months after the termination of vor-
iconazole. She was symptomless with preserved lung allograft function:
Her FEV1 was 2.7 L (77% predicted). Brain MRI revealed only few re-
sidual lesions (Fig. 2d), which had been stable and inactive for months.
3. Discussion
To the best of our knowledge, the presented case is the ﬁrst pub-
lished S. apiospermum disseminated infection with brain and spinal cord
abscesses after LT leading to a full recovery Previous reports have
shown a good response to antifungals with or without surgical drainage
in patients with S. apiospermum local spondylodiscitis, osteomyelitis,
septic arthritis, or lung infections in LT recipients [7,8]. However, the
case reports after LT on both disseminated and CNS involvement have
been disappointing [5,9–14]. Previously reported disseminated S.
apiospermum infections after LT are reviewed in Table 1.
Careful balance in immunosuppression is needed to successfully
manage patients after LT to prevent and treat both the rejection of the
lung allograft and bacterial, viral, and fungal infections. Although less
frequent than bacterial and viral infections, invasive fungal infection is
associated with higher morbidity and mortality after LT [15]. The depth
of immunosuppression is associated with both increased incidence and
worse outcome of invasive fungal infections [5,15].
There is no widely accepted optimal recommendation for antifungal
prophylaxis after LT [15]. The standard regimen used in our institute is
trimethoprim/sulfamethoxazole for Pneumocystis jirovecii. In selected
high-risk patients for Aspergillus infection, we have used nebulized
amphotericin B and short-term systemic caspofungin prophylaxis with
low invasive Aspergillus infection incidence [16]. However, this regimen
has no eﬀect in S. apiospermum. Several positive reports with either
itraconazole, posaconazole or voriconazole prophylaxis have been re-
ported in S. apiospermum colonization, even if the optimal dose or
length of treatment are not well known [3,13]. In contrast, there are
also reports with fatal invasive Scedosporium infections in spite of long-
term voriconazole prophylaxis [13,14]. In our case, we didn't use any
prophylactic antifungal targeted to Scedosporium before LT. After LT,
the patient received inhaled amphotericin B among other prophylactic
agents without measurable prophylactic eﬀects. The use of prophylactic
triazole should be considered for the ﬁrst months after LT or in the
event of temporary additional immunosuppression in high-risk patients
for Scedosporium infections.
Fig. 1. A photograph of the patient's lower extremity: slightly pigmented no-
dules sized one to two cm in diameter with small ulcerations is shown. The
histological ﬁnding was septal panniculitis with fungal culture and nucleic acid
test positive for S. apiospermum.
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Fig. 2. a–d: MRI T2 weighted imaging revealed multiple lesions with perifocal oedema (arrows) (a). Most of the lesions had ring-enhancement with gadolinium
compatible with abscess (arrows). There were also nodular enhancing lesions (arrowheads) (b). Spinal cord MRI shows multiple ring-enhancing lesions (arrows) (c).
The latest control image shows only small residual T2-lesions (arrows) that had remained stable over 8 months after completion of 35 months of voriconazole
treatment (d).
Table 1







Infection sites Antifungal therapy Outcome (Survival time
after diagnosis)
Reference
43 M ITC 18 months Pulmonary, mediastinum, joint, vertebra ITC, CAS, AMB Death (13 months) [13]
57 F ITC 14 months Pulmonary, brain, breast implant, skin VRC, TRB, POS Death (shortly after
diagnosis)
[13]
19 F VRC 1 month Eye, skin, mediastinum, chest wall,
pulmonary, sinus, joint, vertebra
VRC, CAS, TRB, POS,
AMB, PEN
Death (14 months) [13]
20 F None 11 months Kidneys, eye, pulmonary, vertebra NA Death (5 months) [3]
37 F None 2 months Pulmonary, brain, heart, eye ITC, AMB Death (1 month) [3]
64 F None 3 years Pulmonary, septicemia, heart AMB, ITC Death (18 days) [11]
37 F VRC 2 months Skin, brain, septicemia, heart VRC, CAS, TRB Death (6 months) [14]
24 F None 7.5 months Heart, spleen, kidneys, brain ITC, MIC Death (1 month) [14]
30 M None 2 weeks Pulmonary, heart AMB, MIC Death (7 days) [10]
26 F ITC, AMB 3 weeks Skin, eye, brain VRC, MIC Death (6 months) [9]
33 F AMB, ITC, CAS 3 months Joint, pulmonary VRC Alive [8]
27 M None 6 weeks Brain, pulmonary AMB Death (shortly after
diagnosis)
[8]
27 M VRC, AMB 1 month Pulmonary, heart, septic thrombus VRC, TRB, CAS, POS,
ANF, MTF
Death (7 months) [12]
LT, lung transplantation; M, male; ITC, itraconazole; CAS, caspofungin; AMB, amphotericin B; F, female; VRC, voriconazole; TRB, terbinaﬁne; POS, posaconazole;
PEN, pentamidine; NA, Not available; MIC, miconazole; ANF, anidulafungin; MTF, miltefosine.
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The exact dosage, duration or combination of antimycotic therapies
in Scedosporium infections are not well known due to the lack of pro-
spective studies. A successful therapeutic response in 57% of patients
and a median survival time of 133 days were reported in a retrospective
study of 107 patients with Scedosporium infections treated with vor-
iconazole [17]. The median duration of the treatment was 103 days
(range 1–802 days), while 21% of patients received treatment for a year
or more. The initial treatment was similar to our case: intravenous
6mg/kg twice a day for one day, followed by 4mg/kg twice a day after
switching to oral therapy. In another report of an LT patient, an initial
response was seen in a disseminated S. apiospermum infection with
ocular, skin and cerebrospinal ﬂuid involvement [9]. However, a fatal
relapse was seen only two days after the discontinuation of a six-month
treatment period. In our case, we think that the immediate initiation of
voriconazole was important for the good outcome. We used prolonged
intravenous voriconazole regimen for ten months. The main reasons for
that were slow recovery seen in MRI images, lack of side eﬀects, and
fear of inadequate therapeutic levels due to CF-related malabsorption.
Mild photosensitivity reaction was the only adverse event reported by
the patient. In hindsight, an earlier switch to oral treatment with vor-
iconazole and repeated concentration controls could have been pos-
sible. We added miltefosine as combination therapy based on pre-
viously published in vitro susceptibility testing, but the treatment was
terminated due to unwanted side eﬀects and good clinical response to
voriconazole [18].
In conclusion, we reported a lung transplant patient with dis-
seminated S. apiospermum infection with CNS manifestation leading to a
good and rapid response to voriconazole. Considering the preceding
evidence in the literature, we think that prior colonization of
Scedosporium should not be an absolute contraindication for a lung
transplant. However, in the absence of prospective clinical trials, a
careful case-by-case evaluation is needed to prevent and treat dis-
seminated diseases. Especially the role of prophylactic antifungal
therapy, preoperative clearance of potential reservoirs (e.g. sinuses),
use of surgical drainage, and reduced immunotherapy will be needed to
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